AIM ImmunoTech Inc.

CEO interview explores Ampligen's potential to extend survival and improve quality of life as AIM advances toward pivotal development

OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company's investigational dsRNA and highly selective TLR3 agonist immunomodulator.

Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program  Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program

Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) is advancing plans to list its shares on London's AIM market in the fourth quarter of 2026 as it builds its UK presence and progresses commercialisation of its rare earth magnet recycling technology. The proposed AIM admission would complement IonicRE's existing ASX listing and is expected to broaden the company's access to UK and European investors with an interest in critical minerals and the energy transition.

Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and commercial progress. The company is one of a growing band of growth companies to use AIM's new Capital Access Window, a voluntary pause in share trading designed to widen the pool of investors and keep the price stable during a fundraise.

1947 Oil & Gas, a newly listed oil and gas producer focused on US assets, began trading on London's AIM market on Monday with an initial valuation of about £65 million. The company issued 500 million shares at 10p each, raising £50 million through a combination of shares issued to the vendor of Renaissance Offshore and a placing with new investors.

1947 Oil & Gas PLC (AIM:1947) begins trading on AIM today, with shares marked at a premium price and ambitions to lift production from its newly acquired US Gulf of America assets by around 50% over the next two years. In its London IPO, the junior oil and gas raised roughly £30 million at 10p a share to help fund its US$65 million acquisition of Houston-based Renaissance Offshore.